Key Insights

Highlights

Success Rate

93% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 40/100

Termination Rate

3.4%

1 terminated out of 29 trials

Success Rate

92.9%

+6.4% vs benchmark

Late-Stage Pipeline

14%

4 trials in Phase 3/4

Results Transparency

15%

2 of 13 completed with results

Key Signals

2 with results93% success

Data Visualizations

Phase Distribution

20Total
Not Applicable (8)
Early P 1 (1)
P 1 (4)
P 2 (3)
P 3 (1)
P 4 (3)

Trial Status

Completed13
Unknown10
Recruiting2
Active Not Recruiting1
Withdrawn1
Terminated1

Trial Success Rate

92.9%

Benchmark: 86.5%

Based on 13 completed trials

Clinical Trials (29)

Showing 20 of 20 trials
NCT06311396Not ApplicableCompletedPrimary

Development of a Neuronal Microscope

NCT07359586Recruiting

Laryngopharyngeal Injury After Endotracheal Intubation Under General Anesthesia

NCT04246970Not ApplicableEnrolling By Invitation

Prehabilitation and Posttransplant Training Program in Liver Transplantation

NCT06342414Recruiting

An Exosome-Based Liquid Biopsy for the Differential Diagnosis of Primary Liver Cancer

NCT04220944Phase 1Active Not RecruitingPrimary

Combined Locoregional Treatment With Immunotherapy for Unresectable HCC.

NCT06245798CompletedPrimary

Liver Resection for Patients With Hepatocellular Carcinoma and Clinically Significant Portal Hypertension

NCT04682847Unknown

Radiotherapy With Iron Oxide Nanoparticles (SPION) on MR-Linac for Primary & Metastatic Hepatic Cancers

NCT06182865Not ApplicableUnknownPrimary

A Study of Ga-68 Dolacga to Evaluate Liver Reserve Function in Patients With HCC Before and After Proton Therapy

NCT05007548Phase 2CompletedPrimary

to Assess the Accuracy and Reliability of the Ga68-Dolacga Positron Emission Tomography Compared to Computer Tomography Volumetry and Indocyanine Green Retention Test for Measurement of Liver Reserve

NCT02834780Phase 1Completed

Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Participants With Advanced Hepatocellular Carcinoma

NCT06085976Phase 2UnknownPrimary

Efficacy and Safety of Octreotide in Laparoscopic Hepatectomy Surgery: Effect on Blood Loss, Need for Vasoactive Drugs, Transfusion Requirements.

NCT03572582Phase 2Completed

Transarterial Chemoembolization in Combination With Nivolumab Performed for Intermediate Stage Hepatocellular Carcinoma

NCT04775056Withdrawn

A Study to Evaluate Vaccines Against COVID-19 in the Real World

NCT02352935Not ApplicableCompletedPrimary

Percutaneous Irreversible Electroporation for Unresectable Hepatic Carcinoma in Poor Liver Function

NCT02332551Not ApplicableCompletedPrimary

Percutaneous Irreversible Electroporation to Treat Liver Cancer Close to the Gallbladder

NCT05009550Not ApplicableUnknownPrimary

ESP Block on Patient Outcomes in Patients With Liver Tumor Undergoing Radiofrequency Ablation

NCT03164382Phase 3Completed

Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil/Leucovorin Versus Sorafenib in Advanced Hepatocellular Carcinoma

NCT04538313Phase 1UnknownPrimary

A Clinical Study in Patients With High-risk Recurrent Primary Hepatocellular Carcinoma Using Autologous TILs

NCT01760616Phase 4TerminatedPrimary

Huaier Granule for Prevention of Disease Progression of Hepatocarcinoma After Non-radical Hepatectomy

NCT04266548Not ApplicableCompletedPrimary

Arterial Base Fluorescence Segmental Positive Staining

Scroll to load more

Research Network

Activity Timeline